A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Azercabtagene zapreleucel (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
Most Recent Events
- 12 Feb 2025 According to MaxCyte media release, company targeting commencement of a Phase 1 trial in 2025.
- 24 Jan 2025 Status changed from not yet recruiting to recruiting.
- 08 Nov 2024 Status changed from planning to not yet recruiting.